01:56 , Nov 20, 2015 |  BC Extra  |  Financial News

Shkreli investment gives KaloBios lifeline

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) gained $8.33 (402%) to $10.40 after it said Martin Shkreli and associated individuals acquired a majority stake in the company. KaloBios had said Nov. 13 that it would wind down operations...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

KaloBios cancer news

KaloBios will reduce headcount by about 17 (61%) to about 11 to focus resources on development of lenzilumab ( KB003) in chronic monomyelocytic leukemia (CMML) while it evaluates strategic alternatives, including a potential sale of...
02:36 , Jan 7, 2015 |  BC Extra  |  Clinical News

KaloBios drops CF progam after Phase II miss

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The compound missed the...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors EPH receptor A3 (EPHA3) In vitro and mouse studies suggest EPHA3 antibodies could help treat...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

KB004: Preliminary Phase I data

Preliminary data from 44 patients with relapsed or refractory hematologic malignancies in an open-label, dose-escalation, U.S. Phase I trial showed that IV KB004 on days 1, 8 and 15 of a 21-day cycle was well...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

KB003: Development discontinued

KaloBios discontinued development of KB003 to treat severe asthma after top-line data from a double-blind, international Phase II trial in 160 patients with severe asthma inadequately controlled on corticosteroids showed that 400 mg IV KB003...
02:18 , Jan 30, 2014 |  BC Extra  |  Clinical News

KaloBios falls after dropping KB003 for asthma

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) fell $1.45 (31%) to $3.20 in early after-hours trading on Wednesday after the company announced after market close that it discontinued development of KB003 for severe asthma. The decision came after...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

KB004: Phase I started

KaloBios began an open-label, dose-escalation, U.S. Phase I trial to evaluate weekly 20, 70, 200 and 700 mg IV KB004 in a 21-day cycle for up to 17 cycles in up to 24 patients. Following...